What Lineage Cell Therapeutics (LCTX) Said on Its Q3 Earnings Call
Lineage Cell: Q3 Earnings Snapshot
Lineage Cell Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Lineage Announces Acquisition of NeuroAirmid Therapeutics and Clinical Stage Program for the Treatment of Huntington’s Disease
Lineage Acquires NeuroAirmid Therapeutics
Lineage Cell Therapeutics to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026
Lineage Provides Update on ReSonance® Program for Hearing Loss
Transcript: Lineage Cell Therapeutics Q2 2026 Earnings Conference Call
Lineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing Platform
Lineage Cell Therapeutics: Balancing An Out-Licensed Pipeline Against Clinical Risk
Lineage Cell Therapeutics (LCTX) Q2 2026 Earnings Call Transcript
Lineage Cell Therapeutics Q2 Earnings Call Highlights
Lineage Cell Therapeutics, Inc. Q2 2026 Earnings Call Summary
Lineage Cell Therapeutics Inc (LCTX) (Q2 2026) Earnings Call Highlights: Cash Runway Extended, ...
Lineage Cell Therapeutics, Inc. (LCTX) Q2 2026 Earnings Call Transcript
Lineage Cell Therapeutics (NYSEARCA:LCTX) Slips on Q2 Revenue Miss, but EPS In Line and Pipeline Advances
Lineage Cell (LCTX) Reports Q2 Loss, Lags Revenue Estimates
Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026
Lineage Cell Therapeutics Maps COR1 Path With ‘Thaw and Inject’ Cell Therapy Plan
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.